The Best-Selling Drugs In America
Lipitor, the cholesterol-lowering treatment, remains the best-selling drug in America. But Pfizer, the drug’s maker, is facing renewed competition from biotechs like Amgen that were hardly on the map a decade ago– and renewed threats from cheap generic drugs.That’s the picture from newly released data from IMS Health, a pharmaceutical information and consulting company that independently keeps track of how often medicines are prescribed and how much revenue they are generating. IMS has provided to Forbes a list of the top 20 medicines by U.S. sales.
| #1 LIPITOR Treats: High cholesterol Pfizer $8.4 billion +8% |
|
| #2 ZOCOR Treats: High cholesterol Merck $4.4 billion -5% |
|
| #3 NEXIUM Treats: Heartburn AstraZeneca $4.4 billion +15% |
|
| #4 PREVACID Treats: Heartburn Abbott & Takeda $3.8 billion -2% |
|
| #5 ADVAIR DISKUS Treats: Asthma GlaxoSmithKline $3.6 billion +22% |
|
| #6 PLAVIX Treats: Heart disease Bristol-Myers Squibb & Sanofi-Aventis $3.5 billion +15% |
|
| #7 ZOLOFT Treats: Depression Pfizer $3.1 billion -2% |
|
| #8 EPOGEN Treats: Anemia Amgen $3.0 billion -1% |
|
| #9 PROCRIT Treats: Anemia Johnson & Johnson $3.0 billion -9% |
|
| #10 ARANESP Treats: Anemia Amgen $2.8 billion +46% |
|
| #11 ENBREL Treats: Rheumatoid arthritis Amgen & Wyeth $2.7 billion +36% |
|
| #12 NORVASC Treats: High blood pressure Pfizer $2.6 billion +8% |
|
| #13 SEROQUEL Treats: Schizophrenia AstraZeneca $2.6 billion +25% |
|
| #14 EFFEXOR XR Treats: Depression Wyeth $2.6 billion -2% |
|
| #15 ZYPREXA Treats: Schizophrenia Eli Lilly $2.5 billion -16% |
|
| #16 SINGULAIR Treats: Asthma & Allergies Merck $2.5 billion +14% |
|
| #17 PROTONIX Treats: Heartburn Wyeth $2.4 billion +0% |
|
| #18 RISPERDAL Treats: Schizophrenia Johnson & Johnson $2.3 billion +5% |
|
| #19 NEULASTA Treats: Chemotherapy side effects Amgen $2.2 billion +30% |
|
| #20 REMICADE Treats: Rheumatoid arthritis Johnson & Johnson $2.2 billion +12% |
Source: IMS Health, a healthcare information company.















































































































